Grade Study

GRADE Study

Active study, but not enrolling

Who do I contact for more information?

Sarah Kissel, RN or Toni Schweiger, RN
314-747-0070
GRADESTUDY@wustl.edu

Study coordinators

 Sarah Kissel, RN (314) 362-8614 or Carol Recklein, RN (314) 362-8608

Investigator

 Janet McGill, MD

Fox 2 News video on GRADE study

The GRADE study, a diabetes treatment study, is a long term research study designed to compare the effects of adding one of four different diabetes medications to the treatment program of patients who are already taking metformin. The four diabetes medications are recommended by the American Diabetes Association and approved by the FDA to treat type 2 diabetes. Each medication has advantages and disadvantages, but it is not clear which of the four is best for controlling diabetes over the long-term. The goal of GRADE is to try to answer that question.

Participants will

1. have type 2 diabetes diagnosed within the past 10 years
2. be taking metformin and no other diabetes medications
3. have a current HbA1c greater than or equal to 6.8%

Study information

1. The National Institutes of Diabetes and Digestive and Kidney Diseases, part of the NIH, in collaboration with 37 medical clinics, including Washington University School of Medicine, is conducting this study.
2. During the first year there will be about 6 study visits after that there will be 4 visits each year for the next 4 to 7 years.
3. Participants receive physical exams, lab tests (blood draw, urine specimen), Oral Glucose Tolerance Test, memory tests, foot exam, diabetes education and healthy lifestyle guidance and questionnaires.
4. No charge to the participant or their insurance provider.
5. Parking is free and if the participant takes the Metro, fare will be reimbursed. A small travel stipend provided and a $100 payment at each yearly visit.
6. Participant’s primary care doctor will be provided a copy of lab results and up-dates at specific study visits. The study staff will assume responsibility for diabetes medication management but the participant’s primary care doctor will remain responsible for all other care.

Primary outcome measurement

HbA1c results for participants taking the maximum tolerated dose of metformin and the maximum recommended dose of the add-on diabetes medication.

I’m interested who do I contact for more inforation?

Sarah Kissel, RN or Toni Schweiger, RN
314-747-0070
GRADESTUDY@wustl.edu

Study coordinators: Sarah Kissel, RN (314) 362-8614 or Carol Recklein, RN (314) 362-8608
Investigator: Janet McGill, MD

ClinicalTrials.gov Identifier: NCT01794143

For more information on the GRADE Study

GRADE Study website